Why Veru Should Be On Your Radar Moving Forward

Share on facebook
Share on twitter
Share on linkedin
Share on whatsapp

Veru shares climbed higher to set a new high yesterday after the oncology biopharmaceutical company released encouraging results regarding a cancer drug that is being examined.

The company, based in Miami, develops drugs for breast and prostate cancers. The company reported that a prostate cancer treatment appeared quite effective and safe in Phase 2 clinical trial, conducted in patients with acute respiratory distress caused by Covid-19.


The 2021 Backdoor Crypto Portfolio (free)

Even if you’re not actively in crypto, you deserve to know what’s actually going on...

Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.

Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.

Sponsored



Veru announced that VERU-111 showed an 82% reduced mortality or respiratory failure from almost 30 days after treatment as compared with patients who received a placebo.Dr. Mitchell Steiner told Jim Cramer of CNBC that his cancer medicine can be an anti-inflammatory medicine as well as an antiviral to treat the respiratory disease sometimes fatal.

Veru is on course to meet with the U.S. Food and Drug Administration, as part of its efforts to provide individuals with severe cases of Covid-19 with an opportunity to participate in Phase 3 clinical trial.

About 200 hospitalized patients at high risk of acute respiratory distress syndrome are expected to be part of this trial study.40 patients were included in the Phase 2 trial in five sites across the U.S.

Veru aims to complete the clinical phase in the fourth quarter by the end of this year. The company says it will seek funding from the Biomedical Advanced Research and Development Authority of the Department of Health and Human Services to meet supply needs in the U.S.

Sign up for our FREE Newsletter and get:

Leave a Comment

Your email address will not be published. Required fields are marked *

Sign up for our FREE Newsletter and get:

Is Stereotaxis Inc. (STXS) a Keeper?

Stereotaxis Inc. (AMEX:STXS) went up by 0.36% from its latest closing price compared to the recent 1-year high of $8.57. The company’s stock price has

Get The Best Stocks To Trade Every Day!...100% Free

We do not sell or share your information with anyone.

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

We do not sell or share your information with anyone.

Get Best Morning Financial Newsletter... 100% Free

Best stocks ideas

Analysts’ Upgrades & Downgrades

Important Earnings

Insider Watchlist

We do not sell or share your information with anyone.